The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research ...

Patients with asthma and COPD routinely switch from pressurized metered-dose inhalers (pMDIs) to dry powder inhalers (DPIs) and vice versa.

A rapid decline in lung function is linked to the development of chronic obstructive pulmonary disease (COPD) ...

N-acetylcysteine (NAC) nebulizer therapy is effective and safe in the short-term (12 weeks) for reducing phlegm in COPD.

Researchers at Karolinska Institutet and the University of Gothenburg have identified a biomarker that could become an ...

Distinct patterns of symptom severity among patients with COPD sheds light on the heterogeneous nature of the patients’ ...

A study by doctoral student Adriana Eugene and Distinguished Professor Luisa N. Borrell found that older adults who use ...

The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.

Levalbuterol and albuterol act quickly to open your airways during an asthma attack. Find out more about key differences and ...